Not only is DLD significantly related to prognosis in ER+ BC patients, but there is also a significant difference in the expression of dual tamoxifen and fulvestrant-resistant LCC9 cell lines and MCF-7 cell lines sensitive to ET. This evidence concerns the gene ESR1 and breast cancer.